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Objective: We wanted to assess the safety and efficacy of performing radiofrequency ablation (RFA) in patients with non-
colorectal liver metastases.
Materials and Methods: In this retrospective study, 25 patients with 40 hepatic metastases (M:F = 17:8; mean age, 57 
years; tumor size, 0.5-5.0 cm) from a non-colorectal origin (stomach, biliary, breast, pancreas, kidney and skin) were 
treated with RFA. The RFA procedures were performed using either an internally cooled electrode or a clustered electrode 
under ultrasound or CT guidance. Contrast-enhanced CT scans were obtained immediately after RFA and follow-up CT scans 
were performed within three months after ablation and subsequently at least every six months. The intrahepatic disease-
free interval was estimated and the overall survival from the time of the initial RFA was analyzed using the Kaplan-Meier 
method.
Results: No intraprocedural deaths occurred, but four major complications developed, including abscesses (n = 3) and 
pneumothorax (n = 1). Technical effectiveness was determined on the initial follow-up images. During the follow-up period 
(range, 5.9-68.6 months; median time, 18.8 months) for 37 tumors in 22 patients where technical effectiveness was 
achieved, 12 lesions (32%, 12 of 37) showed local tumor progression and new intrahepatic metastases occurred in 13 
patients (59%, 13 of 22). The median intrahepatic disease-free interval was 10.1 months. The 1-year, 3-year and 5-year 
overall survival rates after RFA were 86%, 39% and 19%, respectively.
Conclusion: RFA showed intermediate therapeutic effectiveness for the treatment of non-colorectal origin liver metastases.
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INTRODUCTION
Radiofrequency ablation (RFA) has recently received 
considerable attention as a minimally invasive treatment 
for tumor. The technique has been increasingly used for 
the treatment of hepatocellular carcinoma (HCC) and 
colorectal liver metastases. In patients with a solitary HCC 
and Child-Pugh class A cirrhosis, RFA had been shown to 
be associated with an excellent 5-year survival rate that 
is comparable to surgical resection (1-6). Furthermore, for Korean J Radiol 12(5), Sep/Oct 2011 kjronline.org 580
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the patients with colorectal liver metastases, the 3-year 
and 5-year survival rates after RFA are in the range of 42-
64% and 31-44%, respectively (7-12). Several studies have 
demonstrated that for patients with small solitary colorectal 
metastases, the survival rates after surgical resection and RF 
ablation might be comparable (13-15). Therefore, RFA has 
been increasingly used as an alternative modality to surgery 
for patients with small liver metastases from colorectal 
cancer and who have limited hepatic metastatic disease.
Some parts of eastern Asia, including Korea and Japan, 
have a very high incidence of gastric cancer (16, 17), 
and the patients suffering from tumor recurrence in 
the liver after primary cancer resection are common. 
Cholangiocarcinoma is the second most common primary 
liver cancer after HCC (18). Although many studies have 
demonstrated the therapeutic efficacy and survival of RFA 
for the treatment of liver metastases (19-33), there have 
been only limited studies on using RFA for treating liver 
metastases from non-colorectal cancers such as gastric 
cancers (19-21) and cholangiocarcinomas (22). The 
purpose of this study was to assess the safety and efficacy 
of curative intent RFA for the treatment of metachronous 
isolated liver metastases from non-colorectal cancers, 
including gastric cancers and cholangiocarcinomas. 
MATERIALS AND METHODS
A review of our radiofrequency ablation (RFA) database 
identified that 74 treatment sessions for 58 patients were 
performed for the management of liver metastases from 
non-colorectal cancer between September 2002 and March 
2008. We only included the procedures performed for a 
curative intent of hepatic metastases. The inclusion criteria 
included the following. 1) On the images obtained prior 
to the RFA procedure, the primary cancer was controlled, 
2) inoperable hepatic metastases because of bilobar 
disease, comorbidity, a previous history of liver resection 
or the patient’s refusal, 3) the patients had no detectable 
extrahepatic metastases, 4) the number of metachronous 
hepatic metastases was five or less, 5) the tumor size was 
5cm or less, and 6) the patients had at least one follow-up 
image. We conducted a retrospective review of the imaging 
findings and medical records. The Institutional Review Board 
approved this retrospective study and the requirement for 
patient informed consent was waived.
Patients
Over a 6-year-period, we selected 28 RFA sessions in 
25 patients (M:F = 17:8; age range, 36-83 years; mean 
age, 57 years) that were performed with a curative intent 
for hepatic metastases. The histological diagnosis of the 
primary cancers and the types of treatment for the primary 
cancers are listed in Table 1. The size of the treated 
tumors ranged from 0.5 cm to 5 cm in diameter (mean ± 
standard deviation [SD], 2.0 ± 1.0 cm). The total number 
of RFA treated tumors was 40 with a range of 1-4 per one 
treatment session (mean ± SD, 1.6 ± 0.8).
In our institution, the diagnostic work-up included a 
dynamic abdominal CT examination that was performed 
within one month before the RFA procedure. Laboratory 
tests such as a liver function test, a coagulation test and 
complete blood tests were also performed. All of the tumors 
were 5 cm or less in size. For RFA, the metastases should 
be less than 5 cm in diameter and the tumors should be 
located remote from large vessels, the bowel or diaphragm 
to minimize the risk of complications (34, 35). A platelet 
count of more than 50 × 103/μL and an INR (international 
normalized ratio) of less than 1.5 were required before the 
procedure.
Radiofrequency Ablation Procedure
The patients underwent RFA treatment after 12 hours of 
fasting. For all the patients, RFA therapy was performed 
with conscious sedation and analgesia, which were achieved 
by means of intravenous administration of 1-2 mg of 
midazolam (Dormicum; Roche, Basel, Switzerland) and 50-
100 g of fentanyl citrate (Fentanyl; Myengmun, Seoul, 
Korea). A nurse and the attending physician continuously 
monitored the vital signs during the procedure and for one 
hour following the procedure.
Percutaneous RFA was performed by one of the attending 
physicians with 3-10 years experience in RFA and these 
procedures were mostly done under sonographic guidance 
and monitoring, except for three metastases that were 
not visualized on a sonographic examination and so they 
were treated under CT guidance. RFA was performed using 
a 500-KHz monopolar RF generator (either a CC-1, Integra 
Radionics, Burlington, MA or a multi-channel RF generator, 
Taewoong, Koyang, Korea). A single cool tip electrode 
(Cool Tip Electrode; Valleylab, Boulder, CO) or a clustered 
electrode (Valleylab) was used based on the target tumor 
size. A single cool tip electrode was used for tumors smaller 
than 3 cm and a clustered electrode was used for tumors Korean J Radiol 12(5), Sep/Oct 2011 kjronline.org 581
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Table 1. Patient Characteristics
No. Age Gender Primary Cancer Surgery
Initial 
Pathologic 
Stage
Pre-RFA 
Treatment
Number of Treated 
Tumors/Session Post-RFA 
Treatment
Survival
Follow up 
Duration
(months) #1 
Session
#2
Session
#3
Session
1 38 M Stomach, AGC
Extended total 
gastrectomy
T2N1M0 0 2 4 RTx, CTx No 46
2 66 F Stomach, AGC STG T2N1M0 0 1 CTx No 29
3 67 M Stomach, AGC STG T2N2M0 CTx 1 0 No 11
4 80 F Stomach, AGC TG T3N1M0 CTx 1
Follow-up 
loss
No 13
5 41 M Stomach, AGC TG T3N3M0 CTx 3 CTx No 14
6 70 M Stomach, AGC TG with R en Y T2N3M0 CTx 1 CTx No 15
7 51 M Stomach, AGC TG T2N3M0 CTx 1 CTx No 15
8 63 M Stomach, AGC STG T2N3M0 CTx 1 CTx No 14
9 73 M Stomach, AGC STG T3N3M0 0 1 CTx No 9
10 60 M Stomach, AGC
TG,T-colon R 
& A, E-J, J-J 
colocolostomy
T2N0M0 CTx 1 CTx Yes 39
11 83 M
Biliary, 
intrahepatic
Left lateral 
segmentectomy
T1N1M0 0 3
Follow-up 
loss
No 27
12 73 M
Biliary, 
intrahepatic
Left lobectomy, 
cholecystectomy
T1NxM0
CTx + TACE +
tumorectomy
3
Follow-up 
loss
No 35
13 38 M
Biliary, 
intrahepatic
Extended left 
hemihepatectomy, 
caudate resection
T2N1M0 CTx 1 3 CTx Yes 19
14 55 M
Biliary, 
intrahepatic
Right lobectomy T1N0M0 0 1 1 1 CTx Yes 30
15 53 M
Biliary, 
extrahepatic
PPPD T3N1M0 CTx + RTx 2 1 2 0 No 14
16 59 M
Biliary, 
extrahepatic
PPPD T2N1M0 0 1 1 CTx Yes 69
17 51 M
Biliary, 
extrahepatic
PPPD T1N0M0 0 1 CTx + 
tumorectomy Yes 42
18 71 F Biliary, GB
Cholecystectomy,
right lobectomy
T3N1M0 RTx + CTx 3
Follow-up 
loss
No 9
19 45 F Breast, IDC Right MRM T2N0M0 CTx 1 CTx Yes 23
20 50 F Breast, IDC
Bilateral 
mastectomy
T2N0M0 CTx 2 CTx Yes 6
21 39 F Breast, IDC Right MRM T3N1M0 CTx 1 CTx + RTx Yes 42
22 36 F Breast, IDC
Right 
quadrantectomy
T2N0M0 CTx + RT 1 1 CTx Yes 28
23 51 M Kidney, RCC
Left radical 
nephrectomy
T2N0M0 0 2 CTx Yes 19
24 60 F
Pancreas, 
endocrine tumor
Whipple’s 
operation
T3N0M0 CTx 3 0 Yes 7
25 60 M
Skin, malignant 
melanoma
Skin, subcutis, 
left tibia, excision
T3N0M0 IFN-α, RTx 1
Follow-up 
loss
Yes 7
Note.— AGC = advanced gastric cancer, CTx = chemotherapy, E-J = esophagojejunal anastomosis, GB =gallbladder, IDC = 
intraductal infiltrating carcinoma, J-J = jejunojejunal anastomosis, MRM = modified radical mastectomy, PPPD = pylorus-preserving 
pancreatoduodenectomy, R en Y = Roux-en Y, RCC = renal cell carcinoma, RFA = radiofrequency ablation, RTx = radiation therapy, 
STG = subtotal gastrectomy, T-colon R & A = transverse colon resection and anastomosis, TACE = transarterial chemoembolization, 
TG = total gastrectomyKorean J Radiol 12(5), Sep/Oct 2011 kjronline.org 582
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larger than 3 cm.
Radiofrequency was initially applied for 12 minutes 
and for subsequent ablations for 6 to 12 minutes. An 
impedance-controlled automated pulsed RF algorithm 
was used (upper limit, 80 ohms) with a maximum peak 
current of 1000-2000 mA and 50-200 W. A peristaltic pump 
(Watson-Marlow, Paris, France) was used for cooling of 
the electrode with saline solution (0°C) at a rate that was 
sufficient to maintain an electrode temperature below 20°C. 
Constant monitoring of the temperature at the tip of the 
needle was also performed. After ablation, the electrode 
was withdrawn with cauterizing the tract.
   
Treatment Assessment and Follow Up
Immediately after the completion of the radiofrequency 
ablation procedure, a three-phase dynamic enhanced CT 
study (120 kVp, 200 mAs, 1.5 ml/body weight of nonionic 
contrast) was performed to evaluate the presence of 
residual tumor at the treated site and any immediate 
complications such as hemorrhage and bowel injury. A lack 
of enhancement of the ablated zone that covered the tumor 
area with no evidence of irregular peripheral enhancement 
was considered complete ablation of the macroscopic tumor 
and a technically successful RFA procedure (Fig. 1). Four 
metastases were seen as residual lesions on the immediate 
post-RFA enhanced CT images and additional RFA treatment 
was performed within 24 hours after the initial RFA 
procedure. After additional sonography-guided or CT-guided 
RFA, technically successful RFA was performed for all of the 
treated lesions.
Initial follow-up imaging was performed within three 
months. Standardized time interval imaging was obtained 
A
D
B
E
C
Fig. 1. Imaging findings are shown for approximately 3.6 cm sized gastric cancer liver metastasis that was completely ablated 
(technical success) without recurrence. 
A-E. Pre-ablation contrast-enhanced CT in equilibrium phase (A) shows 3.6 cm sized peripheral enhancing mass located at segment 7. 
Immediate-ablation dynamic contrast-enhanced CT demonstrates complete necrosis of metastasis with lack of enhancement on early arterial (B), 
late arterial (C) and portal venous (D) phase. After eight months, follow-up contrast-enhanced CT image (E) shows cystic change of ablated 
lesion without evidence of recurrence.Korean J Radiol 12(5), Sep/Oct 2011 kjronline.org 583
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at three and six months after the RFA procedure and then 
every six months. Nodular or irregular enhancement seen 
during the follow-up imaging was considered local tumor 
progression. Repeat treatment was performed to treat 
local tumor progression and/or new intrahepatic lesions in 
three patients who had fewer than five foci of intrahepatic 
tumor with no evidence of extrahepatic disease, as seen on 
imaging studies.
   
Statistical Analysis
The intrahepatic disease-free interval was defined as 
the interval between the initial treatment and the first 
appearance of a new lesion in the liver. Overall survival 
from the time of the initial RFA was also analyzed using the 
Kaplan-Meier method. MedCalc software (version 10.1.3.0; 
MedCalc Software, Mariakerke, Belgium) was used for all the 
statistical analyses. 
 
RESULTS
Technical Effectiveness
Complete ablation of macroscopic tumors, as depicted 
on the initial follow-up CT images, and the technical 
effectiveness were confirmed for 22 of 25 (88%) patients 
after initial treatment. The technical effectiveness for 40 
treated lesions was 88% (22 of 25) on a per patient basis 
and 93% (37 of 40 lesions) on a per tumor basis.
   
Intrahepatic Tumor Control
The liver CT imaging follow-up time was 19.2 months 
(range, 2.0-64.9 months; median time, 13.2 months). 
During the follow-up period, no viable tumors were detected 
in the liver in seven patients. Four of these seven patients 
were totally tumor free during the follow-up period, but 
three of the patients developed distant metastases. Among 
the 15 patients with intrahepatic tumor recurrence, nine 
patients also had an extrahepatic metastasis during the 
follow-up period. Among the 15 patients with intrahepatic 
tumor recurrence, seven patients had new metastases that 
were remote from the radiofrequency-treated lesions; two 
patients had local tumor progression and six patients had 
both new metastases and local tumor progression.
   
Local tumor Progression
Among the 40 lesions, three metastases were 
unsuccessfully treated. The patients with the 37 lesions 
that were effectively treated underwent follow-up. The 
overall local tumor progression rate was 32% (12 of 37) for 
all of the totally treated lesions, including 25% (3 of 12) 
for stomach cancer, 43% (6 of 14) for biliary cancer, 60% (3 
of 5) for breast cancer and 0% (0 of 3) for the other tumors 
(Fig. 2).
Intrahepatic Recurrence
The intrahepatic recurrence rate was 68% (15 of 22) for 
the primary treatment session, 66% (6 of 9) for stomach 
cancer, 83% (5 of 6) for biliary cancer and 75% (3 of 4) 
for breast cancer. Intrahepatic recurrence developed in the 
patients with renal cell carcinoma (RCC) liver metastases. 
The intrahepatic remote recurrence rate was 59% (13 of 22) 
for all of the treatment sessions, 83% (5 of 6) for biliary 
cancer, 44% (4 of 9) for stomach cancer and 75% (3 of 4) 
Fig. 2. Rates of local tumor progression after radiofrequency 
ablation.
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Fig. 3. Rates of intrahepatic remote recurrence after 
radiofrequency ablation.
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for breast cancer (Fig. 3).
We calculated the time between RFA treatment and the 
follow-up imaging that showed a new intrahepatic lesion. 
The median intrahepatic disease-free interval was 10.1 
months (Fig. 4). Repeated radiofrequency ablation was 
performed to treat local disease progression and new lesions 
for five patients. One biliary cancer patient underwent two 
curative intent RFA procedures and one palliative intent RFA 
procedure. One additional RFA session with a curative intent 
was performed on one breast cancer patient and one biliary 
cancer patent, respectively, and one additional RFA session 
with a palliative intent was performed on one stomach 
cancer patient and one biliary cancer patent, respectively.
   
Extrahepatic Tumor Recurrence
The extrahepatic recurrence rate was 55% (12 of 22) for 
the primary treatment session, 56% (5 of 9) for stomach 
cancer, 67% (4 of 6) for biliary cancer and 25% (1 of 4) for 
breast cancer. Extrahepatic recurrence also developed in the 
RCC and malignant melanoma patients. Seventy five percent 
of these patients with extrahepatic recurrence combined 
with intrahepatic metastases. Three of them first presented 
with extrahepatic metastases. The mean time between 
RFA treatment and the follow-up imaging showing a new 
extrahepatic lesion was 13.7 months.
    
Survival after Radiofrequency Ablation
The mean follow-up was 23.3 months (range, 5.9-68.6 
months; median time, 18.8 months; n = 25). Thirteen 
patients died during follow-up. The median overall 
survival after radiofrequency ablation was 28.8 months. 
The 1-year, 3-year and 5-year estimated survival rates 
after radiofrequency ablation were 86%, 39% and 19%, 
respectively (Fig. 5). 
Complications
The side effects and complications after RFA are 
summarized in Table 2. No intraprocedural deaths occurred. 
Four major complications occurred. One patient who 
developed a large pneumothorax was treated with a chest-
tube and three patients who developed liver abscesses were 
treated with percutaneous drainage. For the 25 patients, 
the total complication rate was 40% (10 of 25).
DISCUSSION
Our study provides the therapeutic results of percutaneous 
RFA for non-colorectal liver metastases, and the estimated 
survival rate for patients with non-colorectal liver 
Fig. 4. Intrahepatic tumor-free interval after radiofrequency 
ablation.
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Fig. 5. Survival rate after radiofrequency ablation.
Table 2. Side Effects and Complications
Type of Complication Number
Minor complications
Subsegmental atelectasis  
  with a small pleural effusion
1
Focal diaphragmatic injury 1
Focal lung parenchymal injury,
  intravenous thrombus 
  at splenoportal junction
1
Biliary stricture 3
Major complications
Large pneumothorax 1
Liver abscess 3Korean J Radiol 12(5), Sep/Oct 2011 kjronline.org 585
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metastases was 86%, 39% and 19% for one year, three 
years and five years, respectively. These results are not 
as good as the results of the previous studies on RFA in 
patients with colorectal liver metastases, which showed the 
1, 3 and 5-year estimated survival rates were 87-96%, 42-
57% and 24-44%, respectively (7-12).
Although the results of RFA for patients with non-
colorectal liver metastases were not as good as that for 
RFA in patients with colorectal liver metastases, our study 
results might have some clinical meaning. For example, 
surgical resection for a gastric liver metastasis is rarely 
performed, which is different from the treatment of 
colorectal liver metastases. Following curative resection 
of gastric cancer, the liver is the most common site of 
hematogenous metastases and approximately 15% of all 
recurrences were liver metastasis alone (36). However, the 
majority of liver metastases are combined with locoregional 
or peritoneal seeding, and even if a metastasis is confined 
in the liver, bilobar disease is common and so there is a 
very limited number of surgical candidates (36, 37). 
The reported 5-year survival rate after hepatic resection 
of selected patients with resectable gastric liver metastases 
is approximately 30% (38-40). Considering this clinical 
situation, our estimated survival rate after RFA for one 
year, three years and five years was 78%, 22% and 0%, 
respectively, with a median survival of 15.1 months. The 
local tumor control rate of stomach cancer was excellent. 
However, as compared with other metastatic tumors, a 
relatively high rate of intrahepatic remote metastases and 
extrahepatic metastases was found. This recurrence pattern 
has also been reported in previous studies regarding 
surgical resection of gastric liver metastases (36, 41). 
Although our results are not as good as compared with the 
surgical results, a complementary role for RFA should be 
considered when remembering that all our patients were 
in an inoperable state (21, 22, 42). However, because of 
the high rate of remote recurrence of stomach cancer, RFA 
as a sole treatment is ethically unacceptable and systemic 
therapy should also be considered.
Surgical resection is the only potentially curative 
treatment for patients with biliary cancer. However, after 
curative resection, the five-year survival rate for patients 
with tumor-free margins is 20-40% and the operative 
mortality is approximately 10%. Even after curative 
resection, 31-50% of these patients have a recurrence 
in one year, and about half of the cancers recur in the 
remaining liver (43-45). The patients who have had prior 
surgery have a lesser chance of curative resection. In 
addition, postoperative chemotherapy and radiation therapy 
were not significantly identified as being efficacious for 
treating biliary cancer (46, 47). Based on our results, half 
of the patients had complete tumor resection and half of 
the patients had palliative surgery and the latter received 
chemoradiation treatment. Because of bilobar disease or 
having undergone hepatectomy, the patients underwent 
RFA for the treatment of recurred cancer. The local tumor 
progression-free rates on a per lesion-basis were 64% and 
32% for one year and two years, respectively, and the 
median intrahepatic disease free interval was 9.5 months. 
Considering the recurrence rate after surgery, there might 
be some role for RFA to control local tumor in patients with 
unresectable disease.
A small number of breast cancer patients were included 
in our series. None of the patients with breast cancer 
died during the follow-up period (range, 5-42 months; 
mean, 25 months; median, 25 months). New metastases 
were observed in three (75%) of four patients. It was not 
possible to compare our study with the previous studies. 
However, for the intrahepatic tumor control of the previous 
largest study, 58% of the patients developed tumors after a 
4-44 month period (mean, 10 months) (25). In comparison, 
the estimated 10-month intrahepatic recurrence rate in our 
study is similar to the rate in a previous study (27). The 
median intrahepatic disease-free interval determined in our 
study (10.1 months) is similar with the 13-month median 
time to recurrence for surgical resection in a previous 
study (48). However, different patient selection and the 
prior disease status should be considered and our findings 
suggest the usefulness of RFA as an alternative procedure in 
place of surgery. As most of our patients received pre-RFA 
and/or post-RFA chemotherapy and other adjuvant therapy, 
the results of our study were, perhaps, partially due to the 
effects of the previous therapies. Maybe a synergistic effect 
of chemotherapy and RF ablation played a role in our study.
There are several limitations of our study. First, this was a 
retrospective study and some heterogeneity existed for the 
patient characteristics and their tumors. Second, the study 
population was not sufficiently large to demonstrate the 
clinical value of RFA. Despite these limitations, our study 
results are important to provide the preliminary findings 
to evaluate the short-term efficacy of RFA for treating 
non-colorectal liver metastases. A randomized controlled 
prospective trial will be needed to prove the clinical role of 
RFA. Third, we did not always apply RFA for the treatment Korean J Radiol 12(5), Sep/Oct 2011 kjronline.org 586
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of recurred tumors after the initial RFA and we were not 
able to determine the potential maximum role of RFA to 
treat non-colorectal liver metastases.
In summary, RFA showed relatively less therapeutic 
effectiveness for the treatment of non-colorectal origin liver 
metastases as compared with colorectal liver metastases. 
However, the therapeutic results of RFA were not 
disappointing as compared with the therapeutic results of 
surgical resection for liver metastases from the same patient 
population with non-colorectal primary cancer. In addition, 
the low morbidity and mortality rates and the improved 
selectivity of candidates for RFA suggest the possible 
broad application of RFA treatment for liver metastases. 
A prospective randomized trial that will compare systemic 
treatment alone and systemic treatment with RFA for liver 
metastases is needed. 
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